Bruker aim to introduce a portfolio of real time PCR assays within the area of invasive fungal disease (IFD), to sit alongside the Fungiplex Aspergillus and Fungiplex Candida assays. This will allow a more tailored diagnostic approach, supporting the needs of a specific patient population, through a single product range. 
Azoles are the primary therapy in the treatment of Invasive Aspergillosis (IA). As the incidence of IA increases, an increasing amount of secondary azole resistance is reported in clinical Aspergillus fumigatus strains. A. fumigatus is difficult to culture from positive clinical samples, therefore, a PCR assay for the detection of azole resistance would improve diagnosis and guide patient therapy. Bruker are developing an Aspergillus azole resistance real-time PCR assay targeting the TR34 (L98H) and TR46 (Y121F/T289A) mutations in the cyp51A gene as a companion product to the Fungiplex Aspergillus assay.

The development of a real-time PCR assay for the detection of Azole Resistance in Aspergillus fumigatus positive patients